References
- Marchetti P, Lupi R, Del Guerra S, et al. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. Diabetes Care 2009;32(Suppl 2):S178-83.
- Marini MA, Frontoni S, Succurro E, et al. Insulin sensitivity, and β-cell function in relation to hemoglobin A1C. Nutr Metab Cardiovasc Dis 2014;24:27-33.
- Kohnert KD, Augstein P, Zander E, et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009;32:1058-62.
- Kohnert KD, Freyse EJ, Salzsieder E. Glycaemic variability and pancreatic beta-cell dysfunction. Curr Diabetes Rev 2012;8:345-54.
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
- Mastrototaro JJ. The Minimed Continuous Glucose Monitoring System (CGMS). J Pediatr Endocr Metab 1999;12:751-8.
- DeFronzo RA, Abdul-Ghani MA. Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 2011;96:2354-66.
- Vella A, Zinsmeister AR. Predicting diabetes using measures of beta-cell function. Diabetes 2012;61:562-3.
- Del Guerra S, Grupillo M, Masini M, et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev 2007;23:234-8.
- Li Y, Xu L, Shen J, et al. Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract 2010;88:42-7.
- Miao XY, Gu ZY, Liu P, et al. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. Peptides 2013;39:71-9.